LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RANI
Rani Therapeutics Holdings, Inc.
There isn't enough reported data to score RANI yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RANI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
RANI's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RANI PE Valuation
RANI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RANI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect RANI's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus RANI down 174%.
RANI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$0.78 | +$0.28 |
| Q2 2025 | -$0.90 | +$0.28 |
| Q1 2025 | -$0.98 | +$0.31 |
| Q4 2024 | -$1.05 | +$0.28 |
| Q3 2024 | -$1.06 | +$0.97 |
| Q2 2024 | -$1.18 | +$0.82 |
| Q1 2024 | -$1.29 | +$0.65 |
| Q4 2023 | -$1.33 | +$0.57 |
RANI is still losing money, but far less than before: $0.78 per share over the past year, against $2.03 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RANI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RANI on profitability, with a higher operating margin.
RANI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $1.7M | +893% |
| Q2 2021 | $2M | +3168% |
| Q1 2021 | $756K | +811% |
RANI's revenue has grown year over year for four quarters in a row: $2M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -540% | N/A |
| Q2 2026 | -517% | N/A |
| Q1 2026 | -488% | +6496 points |
| Q4 2025 | -584% | N/A |
| Q1 2025 | -6984% | N/A |
| Q2 2021 | -268% | +5382 points |
| Q1 2021 | -688% | +5799 points |
| Q4 2020 | -2354% | N/A |
RANI's operating margin was −540% last quarter, up 6444 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RANI on cash generation, producing positive trailing cash flow while its opponent burns cash.
RANI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.9M | -$2.9M |
| Q2 2026 | -$9.1M | -$3.2M |
| Q1 2026 | -$6.5M | +$1.7M |
| Q4 2025 | $294K | +$9M |
| Q3 2025 | -$5.1M | +$3.5M |
| Q2 2025 | -$5.8M | +$3.3M |
| Q1 2025 | -$8.2M | +$1.2M |
| Q4 2024 | -$8.7M | +$4M |
RANI has burned cash in almost every quarter: −$23M over the past year, against −$28M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RANI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RANI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.3% | +11.8M shares |
| 1 year | +445% | +162M shares |
| 3 years | +713% | +175M shares |
| 5 years | +962% | +180M shares |
RANI has 199M diluted shares, up 445% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RANI Net Leverage
RANI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RANI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 5.7 | Oversold |
RANI's weekly RSI is 33 (neutral) and its Stochastic is 6 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RANI PE vs Healthcare Sector
RANI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RANI on trend strength, trading above more of its moving averages.
RANI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.66 | 20% below |
| 20 week MA | $0.75 | 29% below |
| 50 week MA | $0.98 | 46% below |
| 100 week MA | $1.02 | 48% below |
| 200 week MA | $2.40 | 78% below |
RANI is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RANI on returns for 2026, with the stronger performance.
RANI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.0 | $18.6 | +69% |
| 2022 | $18.6 | $6.05 | -67% |
| 2023 | $6.05 | $3.32 | -45% |
| 2024 | $3.32 | $1.42 | -57% |
| 2025 | $1.42 | $1.40 | -1.4% |
| 2026 YTD | $1.40 | $0.53 | -62% |
RANI has finished four years in a row lower, and it's down 62% so far in 2026.